Canadian Ophthalmological Society (COS) Joint Position Statement on Biosimilar Drugs

October 17, 2022

For Ophthalmologists

October 2022

Biosimilar biologic drugs (biosimilars*) were introduced in the Canadian market in 2009. The first ophthalmic biosimilar for intravitreal injection is expected to be launched in Canada in the late fall of 2022. With this launch, it is expected that use of biosimilars across Canada will rapidly increase.

Read the full position statement here

Canadian Ophthalmological Society (COS) Joint Position Statement on Biosimilar Drugs

Related Reading

Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage

Immediately Sequential Bilateral Cataract Surgery (ISBCS) – Key Points

Recommendations for Conducting Vitreoretinal Surgery During the COVID-19 Pandemic